AgeX Therapeutics, Inc.
About AgeX Therapeutics, Inc.The mission of AgeX is to apply technology related to pluripotent stem cells and telomere biology to aging and age-related disease. AgeX is expected to have three initial areas of focus: 1) the development of pluripotent stem cell-derived brown adipocytes for the treatment of Type II diabetes and potentially obesity; 2) the development of vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease; and 3) Induced Tissue Regeneration (iTR)TM - an emerging technology invented and patented by BioTime scientists that is designed to profoundly reprogram aged tissues in the body in a way that can restore a regenerative phenotype normally expressed only in the first few weeks of human development.
83 articles with AgeX Therapeutics, Inc.
BioTime shareholders will receive one share of AgeX common stock for every 10 shares of BioTime common stock held
BioTime, Inc. today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets.
AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Researc
AgeX Therapeutics, Inc. announced that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will present at the conference Ending Age-Related Diseases: Investment Prospects & Advances in Research, Thursday, July 12 at Cooper Union in New York City.
Distribution to BioTime shareholders as of the Record Date on pro rata basis
Juvenescence closed on an oversubscribed Series A financing worth $50 million. It brings the company’s total fundraising to $63 million.The company is focused on developing therapies to increase healthy human longevity.
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
AgeX Therapeutics, Inc. today announced that it has closed a $5 million equity financing, through the sale of two million AgeX common shares to Juvenescence Ltd.
BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
Draft registration statement filed on Form 10 with the U.S. Securities and Exchange Commission
Bestselling financial writer and visionary joins AgeX Board as Company enters next phase of growth
BioTime, Inc., has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”).
AgeX Therapeutics, Inc. announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH).
BioTime subsidiary, AgeX, to receive up to $3.5 million in cash
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic Investment Conference, March 6-9 in San Diego; Undoing Aging, March 15-17 in Berlin, Germany; and the 10th World Congress and Expo on Cell & Stem Cell Research, March 19-21 in New York City.
AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc., today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit (WSCS) on Thursday, January 25, 2018 at the Hyatt Regency Miami.
AgeX today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging.
AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference
This year’s conference will focus on the theme, “The Path Forward for Regenerative Medicine: Traversing the Lab to the Patient.”
AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economist’s Conference "The Business of Longevity: Health Innovation for an Ageing World" October 27 in Hong Kong
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. , announced today that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co- CEO of BioTime, is giving an interview as part of The Economist magazine’s conference.
BioTime Board Of Directors Approves Distribution Of AgeX Therapeutics, Inc. Shares To BioTme Shareholders
AgeX Therapeutics, Inc. CEO Michael D. West To Participate In Fireside Chat With J. Craig Venter At The Cell & Gene Therapy CEO Forum